YB-1 Knockdown Inhibits the Proliferation of Mesothelioma Cells through Multiple Mechanisms

Y-box binding protein-1 (YB-1) is a multifunctional oncoprotein that has been shown to regulate proliferation, invasion and metastasis in a variety of cancer types. We previously demonstrated that YB-1 is overexpressed in mesothelioma cells and its knockdown significantly reduces tumour cell proliferation, migration, and invasion. However, the mechanisms driving these effects are unclear. Here, we utilised an unbiased RNA-seq approach to characterise the changes to gene expression caused by loss of YB-1 knockdown in three mesothelioma cell lines (MSTO-211H, VMC23 and REN cells). Bioinformatic analysis showed that YB-1 knockdown regulated 150 common genes that were enriched for regulators of mitosis, integrins and extracellular matrix organisation. However, each cell line also displayed unique gene expression signatures, that were differentially enriched for cell death or cell cycle control. Interestingly, deregulation of STAT3 and p53-pathways were a key differential between each cell line. Using flow cytometry, apoptosis assays and single-cell time-lapse imaging, we confirmed that MSTO-211H, VMC23 and REN cells underwent either increased cell death, G1 arrest or aberrant mitotic division, respectively. In conclusion, this data indicates that YB-1 knockdown affects a core set of genes in mesothelioma cells. Loss of YB-1 causes a cascade of events that leads to reduced mesothelioma proliferation, dependent on the underlying functionality of the STAT3/p53-pathways and the genetic landscape of the cell.

[1]  L. Ovchinnikov,et al.  Y-Box Binding Proteins in mRNP Assembly, Translation, and Stability Control , 2020, Biomolecules.

[2]  P. Bhatia,et al.  Critical Role for Cold Shock Protein YB-1 in Cytokinesis , 2020, bioRxiv.

[3]  P. Baas,et al.  Immunotherapy in Malignant Pleural Mesothelioma , 2020, Frontiers in Oncology.

[4]  Yuwei Zhang,et al.  Y‐box protein 1 promotes hypoxia/reoxygenation‐ or ischemia/reperfusion‐induced cardiomyocyte apoptosis via SHP‐1‐dependent STAT3 inactivation , 2020, Journal of cellular physiology.

[5]  I. Kulakovskiy,et al.  YB-3 substitutes YB-1 in global mRNA binding , 2020, RNA biology.

[6]  C. Elizabeth Caldon,et al.  Label free, quantitative single-cell fate tracking of time-lapse movies , 2019, MethodsX.

[7]  L. Jensen,et al.  SnapShot: S-Phase Entry and Exit , 2019, Cell.

[8]  G. Reid,et al.  Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma , 2019, Front. Cell Dev. Biol..

[9]  Hee-Gu Lee,et al.  Regulation of Rho GTPases by RhoGDIs in Human Cancers , 2019, Cells.

[10]  B. Bay,et al.  Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression. , 2019, Cancer letters.

[11]  T. Sudo,et al.  Y‑box‑binding protein 1 inhibits apoptosis and upregulates EGFR in colon cancer. , 2019, Oncology reports.

[12]  Jinxin Zhu,et al.  YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway , 2019, Drug design, development and therapy.

[13]  Y. Li,et al.  HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer , 2018, Cancer science.

[14]  F. Hirsch,et al.  Scientific Advances and New Frontiers in Mesothelioma Therapeutics. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  J. Testa,et al.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas , 2018, Journal of cellular physiology.

[16]  Wen-xian Hu,et al.  The novel KLF4/PLAC8 signaling pathway regulates lung cancer growth , 2018, Cell Death & Disease.

[17]  M. Hentze,et al.  The RNA-binding protein YBX1 regulates epidermal progenitors at a posttranscriptional level , 2018, Nature Communications.

[18]  C. Pirker,et al.  Dysregulated Expression of the MicroRNA miR‐137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Lungen Lu,et al.  Y-box Protein-1 Regulates the Expression of Collagen I in Hepatic Progenitor Cells via PDGFR-β/ERK/p90RSK Signalling , 2017, Stem cells international.

[20]  O. Lavrik,et al.  At the Interface of Three Nucleic Acids: The Role of RNA-Binding Proteins and Poly(ADP-ribose) in DNA Repair , 2017, Acta naturae.

[21]  O. Lavrik,et al.  Y-box-binding protein 1 as a non-canonical factor of base excision repair. , 2016, Biochimica et biophysica acta.

[22]  Dmitriy Sonkin,et al.  TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.

[23]  Y. Oda,et al.  Nuclear expression of Y‐box binding protein‐1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models , 2016, International journal of cancer.

[24]  W. Guo,et al.  YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma , 2016, Oncotarget.

[25]  A. Ridley,et al.  Regulating Rho GTPases and their regulators , 2016, Nature Reviews Molecular Cell Biology.

[26]  B. Milleron,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[27]  R. Baxter,et al.  Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage , 2015, Oncotarget.

[28]  A. Kawaguchi,et al.  Centrosome maturation requires YB-1 to regulate dynamic instability of microtubules for nucleus reassembly , 2015, Scientific Reports.

[29]  B. Ghanim,et al.  Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study , 2015, British Journal of Cancer.

[30]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[31]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[32]  Yan Zhou,et al.  Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes , 2014, Molecular Cancer Research.

[33]  M. Kitagawa,et al.  YB‐1 promotes transcription of cyclin D1 in human non‐small‐cell lung cancers , 2014, Genes to cells : devoted to molecular & cellular mechanisms.

[34]  D. Bell,et al.  CSF1 Is a Novel p53 Target Gene Whose Protein Product Functions in a Feed-Forward Manner to Suppress Apoptosis and Enhance p53-Mediated Growth Arrest , 2013, PloS one.

[35]  M. Lind,et al.  PTEN protein expression in malignant pleural mesothelioma , 2013, Tumor Biology.

[36]  K. Kuroiwa,et al.  YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α , 2013, Cancer Immunology, Immunotherapy.

[37]  A. Rosenwald,et al.  The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival , 2013, Leukemia.

[38]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[39]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[40]  A. Shelling,et al.  YB-1, the E2F pathway, and regulation of tumor cell growth. , 2012, Journal of the National Cancer Institute.

[41]  F. Maldonado,et al.  Miliary mesothelioma: a new clinical and radiological presentation in mesothelioma patients with prolonged survival after trimodality therapy. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  P. Hieter,et al.  YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction, and HER2 amplification , 2011, Oncogene.

[43]  L. Corcos,et al.  Cotranscriptional exon skipping in the genotoxic stress response , 2010, Nature Structural &Molecular Biology.

[44]  H. Izumi,et al.  Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. , 2010, European journal of cancer.

[45]  K. Shirouzu,et al.  YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cells. , 2009, Future Oncology.

[46]  T. Nielsen,et al.  Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy , 2007, Breast Cancer Research.

[47]  M. Zvelebil,et al.  iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53 , 2006, Nature Genetics.

[48]  N. Sonenberg,et al.  Akt-Mediated YB-1 Phosphorylation Activates Translation of Silent mRNA Species , 2006, Molecular and Cellular Biology.

[49]  J. Royds,et al.  Y-box factor YB1 controls p53 apoptotic function , 2005, Oncogene.

[50]  Hua Yu,et al.  Role of Stat3 in Regulating p53 Expression and Function , 2005, Molecular and Cellular Biology.

[51]  M. Ladanyi Implications of P16/CDKN2A deletion in pleural mesotheliomas. , 2005, Lung cancer.

[52]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[53]  M. Lebel,et al.  YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. , 2004, Nucleic acids research.

[54]  P. Vogt,et al.  Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  C. Homer,et al.  The Y-box-binding Protein, YB1, Is a Potential Negative Regulator of the p53 Tumor Suppressor* , 2003, Journal of Biological Chemistry.

[56]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[58]  H. Takano,et al.  Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression , 2000, Oncogene.

[59]  H. Gascan,et al.  Functional Interaction of STAT3 Transcription Factor with the Cell Cycle Inhibitor p21 WAF1/CIP1/SDI1 * , 2000, The Journal of Biological Chemistry.

[60]  A. Grimberg P53 and IGFBP-3: apoptosis and cancer protection. , 2000, Molecular genetics and metabolism.

[61]  H. Takano,et al.  Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. , 1999, Cancer research.

[62]  C. L. Ventola Cancer Immunotherapy, Part 3: Challenges and Future Trends. , 2017, P & T : a peer-reviewed journal for formulary management.

[63]  J. Cai,et al.  HOTAIR: a cancer-related long non-coding RNA. , 2014, Neoplasma.

[64]  David Z. Chen,et al.  METHOD Open Access , 2014 .

[65]  C. Print,et al.  YB-1: oncoprotein, prognostic marker and therapeutic target? , 2013, The Biochemical journal.